Gain Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and Gain Therapeutics (GANX)
Gain Therapeutics Analyst Ratings
Gain Therapeutics Analyst Ratings
Gain Therapeutics Analyst Ratings
Buy Rating Affirmed for Gain Therapeutics Amidst Promising Clinical Trials and Strong Financial Health
Gain Therapeutics Analyst Ratings
Buy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial Performance
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
Gain Therapeutics Analyst Ratings
Gain Therapeutics Analyst Ratings
Oppenheimer Remains a Buy on Gain Therapeutics (GANX)
Gain Therapeutics Analyst Ratings
Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson's Drug Candidate GT-02287
Chardan Capital Reiterates Buy on Gain Therapeutics, Maintains $6 Price Target
Gain Therapeutics Analyst Ratings
Buy Rating for Gain Therapeutics Backed by Strong Preclinical Data and Promising Parkinson's Candidate GT-02287
Buy Rating Affirmed: Gain Therapeutics' Promising GT-02287 Advances Towards Key Clinical Milestones in Parkinson's Disease Treatment
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Humana (HUM) and Boston Scientific (BSX)